We recently published a list of 10 Worst High-Risk High-Reward Growth Stocks To Buy. In this article, we are going to take a ...

Biotech companies make some of the best growth stocks. These firms are at the forefront of medical advances such as gene editing, immunotherapy, artificial intelligence (AI)-driven drug discovery, and ...

analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Arcturus Therapeutics compared ...

The stock has seen a nearly 12% decrease since the announcement. A Robust Treatment Pipeline Arcturus Therapeutics is an mRNA medicines and vaccines company. Its therapies include LUNAR lipid ...

Wells Fargo & Company reduced their target price on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating on the stock in a research report on Friday ...

Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) had its price objective reduced by stock analysts at Canaccord Genuity Group from $74.00 to $68.00 in a research report issued on Monday ...

Stay up to date on Arcturus Therapeutics analyst ratings. If you are interested in following small-cap stock news and performance you can start by tracking it here. Arcturus Therapeutics Holdings ...

Arcturus Therapeutics Holdings Inc. (NASDAQ ... Analyst Myles Minter from William Blair maintained a Buy rating on the stock. Minter anticipates that the Phase II trial results for ARCT-032 ...